2,2,6-Trimethyl-3,4-dithiaheptane

• 分子结构分类: 有机化合物 - 有机硫化合物 - 有机二硫化物
• 英文名称: 2,2,6-Trimethyl-3,4-dithiaheptane
• 英文别名: 1-(tert-butyldisulfanyl)-2-methylpropane
• 化学式: C₈H₁₈S₂
• 分子量: 178.4
• InChiKey: ZVSGZORIEHXCDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] RELEASABLE ANTIBODY CONJUGATES<br/>[FR] CONJUGUÉS D'ANTICORPS LIBÉRABLES
  申请人：QUIAPEG PHARMACEUTICALS AB

  公开号：WO2019171358A1

  公开（公告）日：2019-09-12

  This document provides compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein D is a residue of a cytotoxic or chemotherapeutic compound, which undergoes hydrolysis under physiological conditions to release the cytotoxic or chemotherapeutic compound and which are useful in the treatment of cancer and other diseases.

  本文件提供了化合物的公式(I)，或其药用盐，其中D是细胞毒性或化疗化合物的残基，该残基在生理条件下水解释放出细胞毒性或化疗化合物，并且在癌症和其他疾病的治疗中是有用的。
• MIMETIC COMPOSITIONS AND THE PRODUCTION THEREOF
  申请人：McLaughlin Mark L.

  公开号：US20100216992A1

  公开（公告）日：2010-08-26

  The present invention generally relates to compositions including six membered heterocyclic 1,4-diaza-2-one moieties covalently bonded by a hydrazine bond and processes for producing the same. The compositions of the present invention may be utilized as peptido- and/or proteomimetics, for example,' in connection with alpha-helical proteins, like Bcl-2 proteins.

  本发明通常涉及包括由肼键共价结合的六元杂环1,4-二氮杂-2-酮基团的组合物及其制备方法。本发明的组合物可以用作肽类和/或蛋白质类似物，例如，与α-螺旋蛋白质（如Bcl-2蛋白质）相关联。
• Protein-Polymer-Drug Conjugates
  申请人：Yurkovetskiy Aleksandr

  公开号：US20120321583A1

  公开（公告）日：2012-12-20

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种药物结合物。该结合物包括一种基于蛋白质的识别分子（PBRM）和一个聚合物载体，该载体被一个或多个-LD-D取代，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是分子量≦5 kDa的治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接剂。还公开了用于与PBRM结合形成聚合物-药物-PBRM结合物的聚合物支架，包括结合物的组成，其制备方法以及使用结合物或其组成物治疗各种疾病的方法。
• Auristatin Compounds and Conjugates Thereof
  申请人：Mersana Therapeutics, Inc.

  公开号：US20130309192A1

  公开（公告）日：2013-11-21

  Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently an Auristatin compound. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了Auristatin化合物及其共轭物。该共轭物包括基于蛋白质识别分子（PBRM）的识别分子和被取代一个或多个-LD-D的聚合物载体，其中蛋白质识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的Auristatin化合物。LD和LP是连接治疗剂和PBRM到聚合物载体的连接剂。本文还揭示了用于与PBRM共轭形成聚合物-药物-PBRM共轭物的聚合物支架，包括所述共轭物的组成，其制备方法以及使用共轭物或其组成治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150044160A1

  公开（公告）日：2015-02-12

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供一种药物偶联物。该偶联物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，其取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的，其分子量≦5 kDa，是一种治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接体。还公开了用于与PBRM偶联形成聚合物-药物-PBRM偶联物的聚合物支架，包括所述偶联物的组合物，其制备方法以及使用偶联物或其组合物治疗各种疾病的方法。